Business news

    Cynata Therapeutics (ASX:CYP) adds new sites for diabetic trial

    Article Image

    Cynata Therapeutics (ASX:CYP) has announced that three additional clinical sites have opened for recruitment in the ongoing clinical trial of CYP-006TK in patients with diabetic foot ulcers (DFU).

    The trial aims to enrol a total of 30 patients with DFU and aims to complete recruitment mid-way through 2023 with trial results and top-line data to be released by the end of the year.

    The new sites are located in Perth, Western Australia and the company has also established its unique CYP-006TK manufacturing process locally at the Royal Perth Hospital.

    Cynata Therapeutics says this will help accelerate enrolment in the trial, and it remains confident that its cell therapy products offer a unique solution to those affected by DFUs.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa